The Prostate Cancer Foundation Builds Momentum in China
NEW YORK, Feb. 22, 2012 /PRNewswire/ — Leading U.S. prostate cancer surgeon, Dr. David Samadi often takes time from the operating room in New York City to join the prostate cancer fight overseas. As a robotic surgery and robotic prostatectomy expert, his knowledge and hands-on support is a vital part of the growth and development of international prostate cancer treatment efforts in countries such as the Netherlands, France, Dominican Republic and Israel. Organizations such as the Prostate Cancer Foundation (PCF) are at the forefront of eradicating prostate cancer beyond U.S. borders.
With an almost 20-year history of success in prostate cancer, the U.S. based PCF is dedicating to raising and allocating money for prostate cancer research projects worldwide. Their emphasis on prostate cancer awareness, PSA screenings, and prostate cancer research strives for the most effective use of research dollars, both government funding and private donations.
Next month, the newly formed PCF China will hold The First Annual PCF China Scientific Symposium at the Peking University Wu Jieping Urology Center. The event will draw prostate cancer experts from around the globe to discuss the latest prostate cancer prevention and treatment innovations.
PCF China was formed with the goal of eliminating prostate cancer deaths and further extending the reach of the PCF globally. Dr. David Samadi, Vice Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center, is encouraged by the ever-expanding emphasis on eradicating this deadly disease. “Our prostate cancer battle will not be won in the U.S. alone,” he stressed, “Ultimately, it will be the combined expertise of doctors and scientists from around the globe that gives us the power we need to make prostate cancer a disease of the past.”
Comparatively, Asian men have a lower incidence of prostate cancer than those in the United States. Interestingly, relocation to Western countries seems to increase Asian men’s risk of developing prostate cancer, suggesting that diet and lifestyle may be factors as strong as, or stronger than, genetics. Some prostate cancer research has explored variances in Asian diets and Western diets. “It’s no secret that in the U.S. we consume much higher amounts of processed, fatty foods and foods high in sugar. Asian cultures tend to have much healthier diets consisting of larger quantities of seafood, vegetables, and soy foods,” explained Dr. Samadi, “A lot can be learned from other cultures and lifestyles about reducing prostate cancer risk.”
With the goal of increasing patient access to top prostate cancer treatment, Dr. Samadi’s priorities include international trips several times each year. He routinely works side-by-side with healthcare providers and surgeons overseas, encouraging use of the PSA test for early detection of prostate cancer and sharing his SMART surgery technique (Samadi Modified Advanced Robotic Technique). SMART surgery is a highly accurate robotic surgery procedure developed by Dr. Samadi for removal of cancerous prostates with minimal post operative complications. By performing SMART surgeries in other countries, Dr. Samadi not only saves lives, but also lends first-hand knowledge that helps improve the expertise of prostate cancer surgeons worldwide.
“The PCF has made great strides in solving in the global prostate cancer epidemic. Their ability to involve U.S. prostate cancer experts, both medical and scientific, in international progress is vital to men’s health worldwide. Prostate cancer success will come from collaborating minds and shared experiences from around the globe,” said Dr. Samadi.